We serve Chemical Name:2,5-DICHLORO-P-XYLENE CAS:1124-05-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2,5-DICHLORO-P-XYLENE
CAS.NO:1124-05-6
Synonyms:1,4-Dichloro-2,5-dimethylbenzene;2,5-DICHLORO-P-XYLENE;Benzene, 1,4-dichloro-2,5-dimethyl-;MFCD00000610;EINECS 214-387-0
Molecular Formula:C8H8Cl2
Molecular Weight:175.055
HS Code:2903999090
Physical and Chemical Properties:
Melting point:69-70°C
Boiling point:222.1±35.0 °C at 760 mmHg
Density:1.2±0.1 g/cm3
Index of Refraction:1.539
PSA:
Exact Mass:174.000305
LogP:4.26
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:
Contact us for information like 1,4-Dichloro-2,5-dimethylbenzene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,EINECS 214-387-0 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,EINECS 214-387-0 Use and application,Benzene, 1,4-dichloro-2,5-dimethyl- technical grade,usp/ep/jp grade.
Related News: In addition, although the API and intermediate industries are capital-intensive and technology-intensive industries, new competitors are still joining. 2,5-DICHLORO-P-XYLENE manufacturer One key question for the fixed-duration combo is whether it can sustain remission after treatment has stopped. In the preliminary analysis of the GLOW trial, at three months after treatment ended, 51.9% of the Imbruvica-Venclexta patients had undetectable measurable residual disease (uMRD)—a stringent marker reflecting no signs of cancer—in bone marrow, versus 17.1% for the control group. The rates for peripheral blood were 54.7% and 39% for the two groups, respectively. 2,5-DICHLORO-P-XYLENE supplier Beta Bionics, Inc. recently announced it has received Breakthrough Device designation from the US FDA for its investigational iLet Bionic Pancreas System. 2,5-DICHLORO-P-XYLENE vendor In addition, although the API and intermediate industries are capital-intensive and technology-intensive industries, new competitors are still joining. 2,5-DICHLORO-P-XYLENE factory One key question for the fixed-duration combo is whether it can sustain remission after treatment has stopped. In the preliminary analysis of the GLOW trial, at three months after treatment ended, 51.9% of the Imbruvica-Venclexta patients had undetectable measurable residual disease (uMRD)—a stringent marker reflecting no signs of cancer—in bone marrow, versus 17.1% for the control group. The rates for peripheral blood were 54.7% and 39% for the two groups, respectively.
